DOCSLIB.ORG

FIRMAGON® (Degarelix for Injection)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FIRMAGON® (Degarelix for Injection) FIRMAGON® (degarelix for injection) -------------WARNINGS AND PRECAUTIONS-----------------­ HIGHLIGHTS OF PRESCRIBING INFORMATION • Hypersensitivity: Anaphylaxis, urticaria and angioedema These highlights do not include all the information needed to have been reported. Discontinue Firmagon if a serious use FIRMAGON® (degarelix for injection) safely and hypersensitivity reaction occurs, and manage as clinically effectively. See full prescribing information for indicated. (5.2) FIRMAGON. • Effect on QT/QTc Interval: Androgen deprivation therapy FIRMAGON® (degarelix for injection) for subcutaneous may prolong the QT interval. Consider risks and benefits. administration (5.3) Initial U.S. Approval: 2008 ----------------------ADVERSE REACTIONS----------------------­ ---------------------RECENT MAJOR CHANGES-----------------­ The most commonly observed adverse reactions (≥10%) during Warnings and Precautions, (5.3) 02/2015 FIRMAGON therapy included injection site reactions (e.g., pain, erythema, swelling or induration), hot flashes, increased weight, -----------------------INDICATIONS AND USAGE----------------­ and increases in serum levels of transaminases and gamma­ FIRMAGON is a GnRH receptor antagonist indicated for glutamyltransferase (GGT). (6) treatment of patients with advanced prostate cancer. (1) To report SUSPECTED ADVERSE REACTIONS, contact ------------DOSAGE AND ADMINISTRATION----------------­ Ferring at 1-888-FERRING (1-888-337-7464) or FDA at 1­ • FIRMAGON is for subcutaneous administration only. 800-FDA-1088 or www.fda.gov/medwatch. • Treatment is started with a dose of 240 mg given as two -----------------------DRUG INTERACTIONS---------------------­ injections of 120 mg each. Clinically significant CYP450 pharmacokinetic drug-drug • The starting dose is followed by maintenance doses of interactions are unlikely. (7) 80 mg administered as a single injection every 28 days. (2) -----------------------USE IN SPECIFIC POPULATIONS-------------­ --------------DOSAGE FORMS AND STRENGTHS-------------­ There is no need to adjust the dose for the elderly or in patients • FIRMAGON (degarelix for injection) 120 mg per vial with mild or moderate liver or kidney function impairment. • FIRMAGON (degarelix for injection) 80 mg per vial Patients with severe liver or kidney dysfunction have not been studied and caution is therefore warranted. (8) ------------------------CONTRAINDICATIONS--------------------­ FIRMAGON is contraindicated in: See 17 for PATIENT COUNSELING INFORMATION (and • Patients with previous hypersensitivity reactions to FDA approved Patient Labeling) degarelix. (4) Revised: 02/2015 • Pregnancy Category X. Fetal harm can occur when administered to pregnant women. (4) FULL PRESCRIBING INFORMATION: CONTENTS* 10 OVERDOSAGE 11 DESCRIPTION 1 INDICATIONS AND USAGE 12 CLINICAL PHARMACOLOGY 2 DOSAGE AND ADMINISTRATION 12.1 Mechanism of Action 3 DOSAGE FORMS AND STRENGTHS 12.2 Pharmacodynamics 4 CONTRAINDICATIONS 12.3 Pharmacokinetics 5 WARNINGS AND PRECAUTIONS 13 NONCLINICAL TOXICOLOGY 5.1 Use in Pregnancy 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 5.2 Hypersensitivity Reactions 14 CLINICAL STUDIES 5.3 Effect on QT/QTc Interval 15 REFERENCES 5.4 Laboratory Testing 16 HOW SUPPLIED/STORAGE AND HANDLING 6 ADVERSE REACTIONS 17 PATIENT COUNSELING INFORMATION 7 DRUG INTERACTIONS 17.1 Information 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.3 Nursing Mothers 8.4 Pediatric Use 8.5 Geriatric Use *Sections or subsections omitted from the full prescribing information are 8.6 Renal impairment not listed. 8.7 Hepatic impairment Reference ID: 3704666 FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE FIRMAGON is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer. 2 DOSAGE AND ADMINISTRATION FIRMAGON is for subcutaneous administration only. Dosing information: Starting dose Maintenance dose – Administration every 28 days 240 mg given as two subcutaneous injections 80 mg given as one subcutaneous of 120 mg at a concentration of 40 mg/mL injection at a concentration of 20 mg/mL The first maintenance dose should be given 28 days after the starting dose. FIRMAGON is administered as a subcutaneous injection in the abdominal region. As with other drugs administered by subcutaneous injection, the injection site should vary periodically. Injections should be given in areas of the abdomen that will not be exposed to pressure, e.g., not close to waistband or belt nor close to the ribs. FIRMAGON is supplied as a powder to be reconstituted with Sterile Water for Injection, USP (WFI). The instruction for reconstitution needs to be carefully followed. Administration of other concentrations is not recommended. See Instructions for Proper Use. Instructions for Reconstitution The following information is intended for healthcare professionals only: NOTE: • Reconstituted drug must be administered within one hour after addition of Sterile Water for Injection, USP • Do not shake the vials • Follow aseptic technique FIRMAGON 240 mg – Starting Dose The pack contains 2 sets of FIRMAGON 120 mg vial, Sterile Water for Injection, USP syringe, vial adapter, and administration needle. For each subcutaneous injection, the drug product must be prepared using the following instructions. 1. Uncap vial and wipe the vial rubber stopper with an alcohol pad. Remove the cover from the vial adapter package. Attach the vial adapter to the vial by pressing the adapter down until the spike pushes through the rubber stopper and the adapter snaps in place (see Figure A). 2. Assembly of the syringe is required. Prepare the prefilled syringe by attaching the plunger. 2 Reference ID: 3704666 3. Remove the cap of the prefilled syringe. Attach the syringe to the vial by screwing it on to the adapter. Transfer all Sterile Water for Injection, USP to the vial (see Figure B). 4. With the syringe still attached to the adapter, swirl gently until the liquid looks clear and free of powder or particles (see Figure C). If the powder adheres to the side of the vial above the liquid surface, the vial can be tilted slightly. Avoid shaking to prevent foam formation. A ring of small air bubbles on the surface of the liquid is acceptable. The reconstitution procedure may take, in some cases, up to 15 minutes, but usually takes a few minutes. 5. Turn the vial upside down and draw up to the 3 mL mark on the syringe for injection (see Figure D). Always make sure to withdraw the precise volume and expel any air bubbles. 6. Detach the syringe from the vial adapter and attach the administration needle to the syringe. 7. Immediately after reconstitution, inject 3 mL of FIRMAGON 120 mg slowly. Perform a deep subcutaneous injection. To do so: pinch the skin of the abdomen, elevate the subcutaneous tissue and insert the needle at a 45 degree angle (see Figure E). Do not inject into a vein or muscle. Gently pull back the plunger to check if blood is aspirated. If blood appears in the syringe, the product can no longer be used. Discontinue the injection and discard the syringe and the needle (reconstitute a new dose for the patient). No injections should be given in areas where the patient will be exposed to pressure, e.g., around the belt or waistband or close to the ribs. 8. Repeat the reconstitution procedure for the second 120 mg vial to complete the 240 mg starting dose and choose a different injection site for the second dose. 3 Reference ID: 3704666 FIRMAGON 80 mg – Maintenance Dose The pack contains 1 set of FIRMAGON 80 mg vial, Sterile Water for Injection, USP syringe, vial adapter, and administration needle. For the subcutaneous injection, the drug product must be prepared using the following instructions. 1. Uncap vial and wipe the vial rubber stopper with an alcohol pad. Remove the cover from the vial adapter package. Attach the adapter to the powder vial by pressing the adapter down until the spike pushes through the rubber stopper and the adapter snaps in place (see Figure A). 2. Assembly of the syringe is required. Prepare the prefilled syringe by attaching the plunger. 3. Remove the cap of the prefilled syringe. Attach the syringe to the vial by screwing it on to the adapter. Transfer all Sterile Water for Injection, USP to the vial (see Figure B). 4. With the syringe still attached to the adapter, swirl gently until the liquid looks clear and free of powder or particles (see Figure C). If the powder adheres to the side of the vial above the liquid surface, the vial can be tilted slightly. Avoid shaking to prevent foam formation. A ring of small air bubbles on the surface of the liquid is acceptable. The reconstitution procedure may take, in some cases, up to 15 minutes, but usually takes a few minutes. 5. Turn the vial upside down and draw up to the 4 mL mark on the syringe for injection (see Figure D). Always make sure to withdraw the precise volume and expel any air bubbles. 6. Detach the syringe from the vial adapter and attach administration needle to the syringe. 7. Immediately after reconstitution, inject 4 mL of FIRMAGON 80 mg slowly. Perform a deep subcutaneous injection. To do so: pinch the skin of the abdomen, elevate the subcutaneous tissue and insert the needle at a 45 degree angle (see Figure E). Do not inject into a vein or muscle. Gently pull back the plunger to check if blood is aspirated. If blood appears in the syringe, the product can no longer be used. Discontinue the injection and 4 Reference ID: 3704666 discard the syringe and the needle (reconstitute a new dose for the patient). No injections should be given in areas where the patient will be exposed to pressure, e.g., around the belt or waistband or close to the ribs. 3 DOSAGE FORMS AND STRENGTHS Starting dose One starting dose comprises 240 mg given as two 3 mL injections of 120 mg each. Powder for injection 120 mg: One vial of FIRMAGON 120 mg contains 120 mg degarelix. Each vial is to be reconstituted with a prefilled syringe containing 3 mL of Sterile Water for Injection. 3 mL is withdrawn to deliver 120 mg degarelix at a concentration of 40 mg/mL. Maintenance dose One maintenance dose comprises 80 mg given as one 4 mL injection.
Load more

Recommended publications
  • Personalized ADT
    Personalized ADT Thomas Keane MD Conflicts • Ferring • Tolemar • Bayer • Astellas • myriad Personalized ADT for the Specific Paent • Cardiac • OBesity and testosterone • Fsh • High volume metastac disease • Docetaxol • Significant LUTS Cardiovascular risk profile and ADT Is there a difference? Degarelix Belongs to a class of synthe@c drug, GnRH antagonist (Blocker) GnRH pGlu His Trp Ser Tyr Gly Leu Arg Pro Gly NH2 Leuprolide D-Leu NEt Goserelin D-Ser NH2 LHRH agonists Triptorelin D-Trp NH2 Buserelin D-Ser NEt Degarelix D-NaI D-Cpa D-PaI Aph D-Aph D-Ala NH2 N-Me ABarelix D-NaI D-Cpa D-PaI D-Asn Lys D-Ala NH2 Tyr GnRH antagonists Cetrorelix D-NaI D-Cpa D-PaI D-Cit D-Ala NH2 Ganirelix D-NaI D-CPa D-PaI D-hArg D-hArg D-Ala NH2 Millar RP, et al. Endocr Rev 2004;25:235–75 Most acute CVD events are caused By rupture of a vulnerable atherosclero@c plaque The vulnerable plaque – thin cap with inflammaon Inflammation Plaque instability is at the heart of cardiovascular disease Stable plaque Vulnerable plaque Lumen Lumen Lipid core Lipid core FiBrous cap FiBrous cap Thick Cap Thin Rich in SMC and matrix Composion Rich in inflammatory cells: proteoly@c ac@vity Poor Lipid Rich Inflammatory Inflammatory state Highly inflammatory LiBBy P. Circulaon 1995;91:2844-2850 Incidence of Both prostate cancer and CV events is highest in older men Prostate cancer CV events 3500 3500 Prostate cancer All CV disease Major CV events 3000 3000 2827.1 2500 2500 2338.9 2000 2000 1719.7 1500 1500 1152.6 1008.7 1038.7 1000 1000 641.2 545.2 571.1 Age-specific incidence per 100,000 person-years 500 500 246.9 133.7 4.3 0 0 40-49 50-59 60-69 70-79 80-89 90-99 40-49 50-59 60-69 70-79 80-89 90-99 CV, cardiovascular Major CV events = myocardial infarc@on, stroke, or death due to CV disease All CV disease = major CV events + self-reported angina or revascularisaon procedures Driver, et al.
    [Show full text]
  • Degarelix for Treating Advanced Hormone- Dependent Prostate Cancer
    CONFIDENTIAL UNTIL PUBLISHED NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Final appraisal determination Degarelix for treating advanced hormone- dependent prostate cancer This guidance was developed using the single technology appraisal (STA) process 1 Guidance 1.1 Degarelix is recommended as an option for treating advanced hormone-dependent prostate cancer, only in adults with spinal metastases who present with signs or symptoms of spinal cord compression. 1.2 People currently receiving treatment initiated within the NHS with degarelix that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop. 2 The technology 2.1 Degarelix (Firmagon, Ferring Pharmaceuticals) is a selective gonadotrophin-releasing hormone antagonist that reduces the release of gonadotrophins by the pituitary, which in turn reduces the secretion of testosterone by the testes. Gonadotrophin- releasing hormone is also known as luteinising hormone-releasing hormone (LHRH). Because gonadotrophin-releasing hormone antagonists do not produce a rise in hormone levels at the start of treatment, there is no initial testosterone surge or tumour stimulation, and therefore no potential for symptomatic flares. National Institute for Health and Care Excellence Page 1 of 71 Final appraisal determination – Degarelix for treating advanced hormone-dependent prostate cancer Issue date: April 2014 CONFIDENTIAL UNTIL PUBLISHED Degarelix has a UK marketing authorisation for the ‘treatment of adult male patients with advanced hormone-dependent prostate cancer’. It is administered as a subcutaneous injection. 2.2 The most common adverse reactions with degarelix are related to the effects of testosterone suppression, including hot flushes and weight increase, or injection site reactions (such as pain and erythema).
    [Show full text]
  • Degarelix Acetate (Firmagon) Reference Number: PA.CP.PHAR.170 Effective Date: 01/18 Last Review Date: 10/18 Revision Log
    Clinical Policy: Degarelix Acetate (Firmagon) Reference Number: PA.CP.PHAR.170 Effective Date: 01/18 Last Review Date: 10/18 Revision Log Description The intent of the criteria is to ensure that patients follow selection elements established by Pennsylvania Health and Wellness® clinical policy for the use of Degarelix Acetate (Firmagon®). FDA Approved Indication(s) Firmagon is indicated for treatment of advanced prostate cancer. Policy/Criteria It is the policy of Pennsylvania Health and Wellness that Firmagon is medically necessary when the following criteria are met: I. Initial Approval Criteria A. Prostate Cancer (must meet all): 1. Diagnosis of prostate cancer; 2. Prescribed by or in consultation with an oncologist; 3. Request meets one of the following (a, b or c): a. Starting dose does not exceed 240 mg given as two injections of 120 mg each; b. Maintenance dose does not exceed 80 mg as a single injection per 28 days; c. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off- label use (prescriber must submit supporting evidence). Approval duration: 12 months B. Other diagnoses/indications: Refer to PA.CP.PMN.53 1. The following NCCN recommended uses for Firmagon, meeting NCCN categories 1, 2a, or 2b, are approved per the PA.CP.PMN.53: II. Continued Approval A. Prostate Cancer (must meet all): 1. Currently receiving medication via Pennsylvania Health and Wellness benefit or member has previously met approval criteria or the Continuity of Care policy (PA.LTSS.PHAR.01) applies; 2. Member is responding positively to therapy; 3. If request is for a dose increase, request meets one of the following: a.
    [Show full text]
  • Follicular and Endocrine Profiles Associated with Different Gnrh
    Reproductive BioMedicine Online (2012) 24, 153– 162 www.sciencedirect.com www.rbmonline.com ARTICLE Follicular and endocrine profiles associated with different GnRH-antagonist regimens: a randomized controlled trial Juan Antonio Garcı´a-Velasco a, Sanja Kupesic b, Antonio Pellicer c, Claire Bourgain d, Carlos Simo´n e, Milan Mrazek f, Paul Devroey g, Joan-Carles Arce h,* a IVI Foundation, Reproductive Endocrinology, Madrid, Spain; b Texas Tech University Health Sciences Center, Department of Obstetrics and Gynecology, El Paso, TX, USA; c IVI Foundation, Reproductive Endocrinology, Valencia, Spain; d UZ Brussel, Department of Pathology, Brussels, Belgium; e IVI Foundation, Research Department, Valencia, Spain; f ISCARE IVF a.s., Lighthouse, Prague, Czech Republic; g UZ Brussel, Centre for Reproductive Medicine, Brussels, Belgium; h Reproductive Health, Global Clinical and Non-Clinical R & D, Ferring Pharmaceuticals, Copenhagen, Denmark * Corresponding author. E-mail address: [email protected] (J.-C. Arce). Dr Juan Garcı´a-Velasco did his training in obstetrics and gynaecology at Madrid Autonoma University, and then his reproductive endocrinology and infertility fellowship at Yale University, USA (1997–1998). He is now Director of IVI-Madrid and Associate Professor at Rey Juan Carlos University. He has published over 100 peer- reviewed articles. He is an ad-hoc reviewer for the main journals in the field and serves on the editorial board of Reproductive BioMedicine Online. His main research interests are endometriosis, ovarian hyperstimulation syndrome, low responders and human implantation. Abstract This trial assessed the impact of early initiation of gonadotrophin-releasing hormone (GnRH) antagonist on follicular and endocrine profiles compared with the fixed GnRH-antagonist protocol.
    [Show full text]
  • Gnrh Antagonists Have Direct Inhibitory Effects on Castration-Resistant Prostate
    Author Manuscript Published OnlineFirst on July 24, 2019; DOI: 10.1158/1535-7163.MCT-18-1337 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. GnRH antagonists have direct inhibitory effects on castration-resistant prostate cancer via intracrine androgen and AR-V7 expression. Vito Cucchiara1*, Joy C. Yang1*, Chengfei Liu1, Hans H. Adomat2, Emma S. Tomlinson Guns2, Martin E. Gleave2, Allen C. Gao1,3, Christopher P. Evans1,3 1Department of Urologic Surgery, University of California at Davis, Sacramento, California. 2Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada 3UC Davis Comprehensive Cancer Center, University of California Davis, California. Running title: GnRH antagonist inhibits intracrine androgen and AR-V7 Keywords: Prostate Cancer, ADT, GnRH antagonist, intracrine androgen Financial Support: This work is supported in part by grants DOD PC150040P1 and Ferring Pharmaceuticals to CP Evans. Conflicts of Interest: Research support from Ferring to CPE and JCY. All other authors have no conflicts of interest. Corresponding Author: Christopher P. Evans, MD, FACS Professor and Chairman, Department of Urology Urologic Surgical Oncology University of California, Davis, School of Medicine 4860 Y St., Suite 3500 Sacramento, CA 95817 academic office tel # (916)734-7520 academic office fax # (916)734-8094 email: [email protected] *These authors contributed equally to this work Downloaded from mct.aacrjournals.org on October 6, 2021. © 2019 American Association for Cancer Research. Author Manuscript Published OnlineFirst on July 24, 2019; DOI: 10.1158/1535-7163.MCT-18-1337 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
    [Show full text]
  • 214621Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 214621Orig1s000 MULTI-DISCIPLINE REVIEW Summary Review Office Director Cross Discipline Team Leader Review Clinical Review Non-Clinical Review Statistical Review Clinical Pharmacology Review NDA/BLA Multi-disciplinary Review and Evaluation: NDA 214, 621 Relugolix NDA/BLA Multi-disciplinary Review and Evaluation Disclaimer: In this document, the sections labeled as “The Applicant’s Position” are completed by the Applicant, which do not necessarily reflect the positions of the FDA. Application Type NDA Application Number(s) NDA 214621 Priority or Standard Priority Submit Date(s) April 20, 2020 Received Date(s) April 20, 2020 PDUFA Goal Date December 20, 2020 Division/Office OND/CDER/OOD/DO1 Review Completion Date Established Name Relugolix (b) (4) (Proposed) Trade Name Pharmacologic Class Gonadotropin-releasing hormone (GnRH) receptor antagonist Code name TAK-385 Applicant Myovant Sciences, Inc. Formulation(s) oral tablet Dosing Regimen One time loading dose of 360 mg followed by 120 mg daily Applicant Proposed RELUGOLIX is a gonadotropin-releasing hormone Indication(s)/Population(s) (GnRH) antagonist indicated for the treatment of patients with advanced prostate cancer. Recommendation on Regular approval Regulatory Action Recommended RELUGOLIX is a gonadotropin-releasing hormone Indication(s)/Population(s) (GnRH) antagonist indicated for the treatment of (if applicable) patients with advanced prostate cancer. 1 Version date: January 2020 (ALL NDA/ BLA reviews) Disclaimer: In this document, the sections labeled as “The Applicant’s Position” are completed by the Applicant and do not necessarily reflect the positions of the FDA. Reference ID: 4719259 NDA/BLA Multi-disciplinary Review and Evaluation: NDA 214, 621 Relugolix Table of Contents Reviewers of Multi-Disciplinary Review and Evaluation ..................................................
    [Show full text]
  • LHRH Analogues and Degarelix for Treatment of Prostate Cancer – Sorted by Drug
    LHRH analogues and degarelix for treatment of prostate cancer – sorted by drug Drug Degarelix Goserelin Leuprorelin Triptorelin Drug & Dose Degarelix Goserelin Goserelin Leuprorelin Leuprorelin Leuprorelin Leuprorelin Triptorelin Triptorelin Triptorelin Triptorelin 80mg 3.6mg 10.8mg 3.75mg 3.75mg 11.25mg 22.5mg 3mg 3.75mg 11.25mg 22.5mg Administration Monthly 28 days 12 weekly Monthly Monthly 3 monthly 3 monthly 28 days 4 weekly 3 monthly 6 monthly interval Brand Name Firmagon Zoladex Zoladex Lutrate Prostap SR Prostap 3 Lutrate 3 Decapeptyl Gonapeptyl Decapeptyl Decapeptyl LA Depot DCS DCS month SR Depot SR SR 3.75mg Depot Form Powder with Implant in Implant in Powder for Powder plus Powder plus Powder for Powder for Powder for Powder for Powder for a prefilled prefilled prefilled suspension solvent in solvent in suspension suspension suspension suspension suspension syringe syringe syringe with diluent prefilled prefilled with diluent with diluent with vehicle with diluent with diluent containing in syringe syringe syringe syringe (in ampoule) filled (in ampoule) (in solvent. syringe ampoule) Administration Monthly 28 days 12 weekly Monthly Monthly 3 monthly 3 monthly 28 days 4 weekly 3 monthly 6 monthly interval Needle safety No Yes Yes Yes Yes Yes No No No No No device Needle size 25 gauge 16 gauge 14 gauge 20 gauge 23 gauge 23 gauge 20 gauge 20 gauge 21 gauge 20 gauge 20 gauge Injection route Deep S/C S/C S/C I/M S/C or I/M S/C I/M I/M S/C or I/M I/M I/M Injection site Abdomen Anterior Anterior Upper outer Arm, thigh Arm, thigh Upper outer Buttock SC (e.g.
    [Show full text]
  • Firmagon®) SMC No
    degarelix 120mg and 80mg powder and solvent for solution for injection (Firmagon®) SMC No. (560/09) Ferring Pharmaceuticals Ltd 17 December 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a resubmission degarelix (Firmagon®) is accepted for use within NHS Scotland. Indication under review: degarelix is a gonadotropin-releasing hormone (GnRH) antagonist indicated for the treatment of adult male patients with advanced hormone-dependent prostate cancer. In one study that included patients with all stages of prostate cancer, degarelix was shown to be non-inferior to a luteinising hormone releasing hormone (LHRH) agonist in suppressing testosterone levels over a one year treatment period without an initial testosterone flare. This SMC advice takes account of the benefits of a patient access scheme (PAS) that improves the cost-effectiveness of degarelix. This SMC advice is contingent upon the continuing availability of the patient access scheme in NHS Scotland. Overleaf is the detailed advice on this product. Chairman, Scottish Medicines Consortium Published 17 January, 2011 1 Indication Degarelix is a gonadotropin-releasing hormone (GnRH) antagonist indicated for the treatment of adult male patients with advanced hormone-dependent prostate cancer. Dosing Information Starting dose: 240mg (administered as two 120mg/3mL subcutaneous injections). Maintenance dose: 80mg/4mL administered as one subcutaneous injection every month. Product availability date 5 May 2009 Summary of evidence on comparative efficacy Degarelix is a novel testosterone ablating therapy that acts as an antagonist at the gonadatropin releasing hormone (GnRH) receptor.
    [Show full text]
  • Gonadotropin-Releasing Hormone Antagonists Versus Standard Androgen Suppression Therapy for Advanced Prostate Cancer a Systematic Review with Meta-Analysis
    Open Access Research BMJ Open: first published as 10.1136/bmjopen-2015-008217 on 13 November 2015. Downloaded from Gonadotropin-releasing hormone antagonists versus standard androgen suppression therapy for advanced prostate cancer A systematic review with meta-analysis Frank Kunath,1,2 Hendrik Borgmann,2,3 Anette Blümle,4 Bastian Keck,1 Bernd Wullich,1,2 Christine Schmucker,4 Danijel Sikic,1 Catharina Roelle,1 Stefanie Schmidt,2 Amr Wahba,5 Joerg J Meerpohl4 To cite: Kunath F, ABSTRACT et al Strengths and limitations of this study Borgmann H, Blümle A, . Objectives: To evaluate efficacy and safety of Gonadotropin-releasing gonadotropin-releasing hormone (GnRH) antagonists ▪ hormone antagonists versus We searched CENTRAL, MEDLINE, Web of compared to standard androgen suppression therapy standard androgen Science, EMBASE, trial registries and conference suppression therapy for for advanced prostate cancer. books. Two authors independently screened advanced prostate cancer A Setting: The international review team included identified articles, extracted data, evaluated risk systematic review with meta- methodologists of the German Cochrane Centre and of bias and rated quality of evidence according analysis. BMJ Open 2015;5: clinical experts. to GRADE. e008217. doi:10.1136/ Participants: We searched CENTRAL, MEDLINE, Web ▪ There were no statistically significant differences bmjopen-2015-008217 of Science, EMBASE, trial registries and conference in overall mortality, treatment failure, or prostate- books for randomised controlled trials (RCT) for specific antigen progression and no study ▸ Prepublication history for effectiveness data analysis, and randomised or non- reported cancer-specific survival or clinical this paper is available online. randomised controlled studies (non-RCT) for safety progression. To view these files please data analysis (March 2015).
    [Show full text]
  • Elagolix for Treating Endometriosis
    Elagolix for Treating Endometriosis Evidence Report June 15, 2018 Prepared for ©Institute for Clinical and Economic Review, 2018 ICER Staff/Consultants University of Colorado Skaggs School of Pharmacy Modeling Group* Steven J. Atlas, MD, MPH R. Brett McQueen, PhD Director, Primary Care Research and Quality Assistant Professor Improvement Network Department of Clinical Pharmacy Massachusetts General Hospital Center for Pharmaceutical Outcomes Research Geri Cramer, BSN, MBA Jonathan D. Campbell, PhD Research Lead, Evidence Synthesis Associate Professor Institute for Clinical and Economic Review Department of Clinical Pharmacy Center for Pharmaceutical Outcomes Research Patricia G. Synnott, MALD, MS Senior Research Lead, Evidence Synthesis Melanie D. Whittington, PhD Institute for Clinical and Economic Review Research Instructor Department of Clinical Pharmacy Varun Kumar, MBBS, MPH, MSc Health Economist Samuel McGuffin Institute for Clinical and Economic Review Professional Research Assistant Department of Clinical Pharmacy Celia Segel, MPP Program Manager Institute for Clinical and Economic Review Daniel A. Ollendorf, PhD Chief Scientific Officer *The role of the University of Colorado Skaggs Institute for Clinical and Economic Review School of Pharmacy Modeling Group is limited to the development of the cost-effectiveness Steven D. Pearson, MD, MSc model, and the resulting ICER reports do not President necessarily represent the views of CU. Institute for Clinical and Economic Review DATE OF PUBLICATION: June 15, 2018 Steven Atlas served as the lead author for the report. Geri Cramer and Patricia Synnott led the systematic review and authorship of the comparative clinical effectiveness section. Varun Kumar was responsible for oversight of the cost-effectiveness analyses and developed the budget impact model.
    [Show full text]
  • Scottish Medicines Consortium
    Scottish Medicines Consortium degarelix 120mg, 80mg powder and solvent for solution for injection (Firmagon ) No. (560/09) Ferring Pharmaceuticals Limited 10 July 2009 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following a full submission degarelix (Firmagon ) is not recommended for use within NHS Scotland for the treatment of adult male patients with advanced hormone-dependent prostate cancer. In one study that included patients with all stages of prostate cancer, degarelix was shown to be non-inferior to a luteinising hormone releasing hormone (LHRH) agonist in suppressing testosterone levels over a one year treatment period without an initial testosterone flare. However the benefit relative to current Scottish practice involving use of an LHRH agonist plus a short course of anti-androgen therapy to prevent flare is unclear. The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC. Overleaf is the detailed advice on this product. Chairman, Scottish Medicines Consortium Published 10 August 2009 1 Indication Degarelix is a gonadotropin releasing hormone (GnRH) antagonist indicated for the treatment of adult male patients with advanced hormone-dependent prostate cancer. Dosing information Starting dose: 240mg (administered as two 120mg/3mL subcutaneous injections) Maintenance dose: 80mg/4mL administered as one subcutaneous injection every month Product availability date 01 May 2009 Summary of evidence on comparative efficacy Degarelix is a novel testosterone ablating therapy that acts as an antagonist at the gonadatropin releasing hormone (GnRH) receptor.
    [Show full text]
  • Firmagon, INN-Degarelix
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT FIRMAGON 80 mg powder and solvent for solution for injection FIRMAGON 120 mg powder and solvent for solution for injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION FIRMAGON 80 mg powder and solvent for solution for injection Each vial contains 80 mg degarelix (as acetate). After reconstitution, each ml of solution contains 20 mg of degarelix. FIRMAGON 120 mg powder and solvent for solution for injection Each vial contains 120 mg degarelix (as acetate). After reconstitution, each ml of solution contains 40 mg of degarelix. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Powder and solvent for solution for injection Powder: white to off-white powder. Solvent: clear, colourless solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications FIRMAGON is a gonadotrophin releasing hormone (GnRH) antagonist indicated for treatment of adult male patients with advanced hormone-dependent prostate cancer. 4.2 Posology and method of administration Posology Starting dose Maintenance dose – monthly administration 240 mg administered as two consecutive 80 mg administered as one subcutaneous subcutaneous injections of 120 mg each injection The first maintenance dose should be given one month after the starting dose. The therapeutic effect of degarelix should be monitored by clinical parameters and prostate specific antigen (PSA) serum levels. Clinical studies have shown that testosterone (T) suppression occurs immediately after administration of the starting dose with 96% of the patients having serum testosterone levels corresponding to medical castration (T≤0.5 ng/ml) after three days and 100% after one month.
    [Show full text]